Ironwood Pharmaceuticals is trading 10.05% higher at $4.43 following its November 5, 2026, earnings report and raised full-year outlook. - The company raised 2026 revenue guidance to $485–$510 million and adjusted EBITDA guidance to more than $350 million, citing stronger LINZESS expectations. - Third-quarter revenue was $133.0 million, and LINZESS U.S. sales were $324.9 million. - Shares also gained 6.90% on November 5.